A New and Efficient Solid Phase Synthesis of Hydroxamic Acids.
Explore the source record for details and available documents.
Journal Article↗
SEARCH · Search PubMed
Results for “Hydroxamic Acids”
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Direct evidence for a ruthenium(IV) oxo complex-mediated oxidation of a hydroxamic acid in the presence of phosphine oxide donors.
Ruthenium(II) complexes can be used to oxidise N-Boc hydroxylamine the the presence of tert-butylhydroperoxide to the corresponding nitroso dienophile, which is trapped using cyclohexa-1,3-diene as the hetero-Diels-Alder adduct; direct evidence has been obtained for the intervention of a triphenylphosphine oxide-stabilised ruthenium(IV) oxocomplex as the catalytically active species.
Journal Article↗
The action of beta-hydroxylamine cinnamonyl hydroxamic acid (HCHA) on cardiovascular dynamics.
Explore the source record for details and available documents.
Animals↗
Histone deacetylase inhibitors and anticancer therapy.
Recent reports have shown that pharmacological manipulation of chromatin remodeling by histone deacetylase (HDAC) inhibitors, might develop into a potent and specific strategy for the treatment of cancer. Alterations in histone acetylation may lead to changes in chromatin structure and transcriptional dysregulation of genes that are implicated in controlling either cell cycle progression or pathways regulating cell differentiation and/or apoptosis. Dimethyl sulphoxide was one of the first chemicals to be identified as an inducer of transformed cell differentiation. In the class of HDAC inhibitors, now included a short-chain fatty acids, such as 4-phenylbutyrate and valporic acid, hydroxamic acids, such as suberoylanilide hydroxamic acid (SAHA), pyroxamide, trichostatin A, oxamflatin and CHAPSs, cyclic tetrapeptides, such as trapoxin, apicidin and depsipeptide-also known as FK-228 or FR 901228, and benzamides, such as MS-275. First clinical studies have shown that histone hyperacetylation can be achieved safely in humans and that treatment of cancer with such agents seems to become possible. Thus, HDAC inhibitors remains one of the most promising class of new anticancer agents. Further studies are needed in order to delineate the optimal dosage, the duration of therapy and possibly the efficacy of other agents able to synergize with HDAC inhibitors in the fight against cancer.
Animals↗
A robust small-molecule microarray platform for screening cell lysates.
Herein we report the expanded functional group compatibility of small-molecule microarrays to include immobilization of primary alcohols, secondary alcohols, phenols, carboxylic acids, hydroxamic acids, thiols, and amines on a single slide surface. Small-molecule "diversity microarrays" containing nearly 10,000 known bioactive small molecules, natural products, and small molecules originating from several diversity-oriented syntheses were produced by using an isocyanate-mediated covalent capture strategy. Selected printed bioactive compounds were detected with antibodies against compounds of interest. The new surface of the diversity microarrays is highly compatible with approaches involving cellular lysates. This feature has enabled a robust, optimized screening methodology using cellular lysates, allowing the detection of specific interactions with a broad range of binding affinity by using epitope-tagged or chimeric fluorescent proteins without prior purification. We believe that this expanded research capability has considerable promise in biology and medicine.
Cell Line↗
Antitumor imidazotetrazines. 20. Preparation of the 8-acid derivative of mitozolomide and its utility in the preparation of active antitumor agents.
The preparation of 3-(2-chlorethyl)-4-oxo-3H-imidazo[5,1-d]-1,2,3,5- tetrazine-8-carboxylic acid, a key derivative of mitozolomide in our exploration of the structure-activity relationships of this class of antitumor agents, is described. The facile conversion to the 8-carbonyl chloride gave a derivative that reacted preferentially with nucleophiles at the 8-position rather than at the reactive 4-oxo group, allowing the preparation of a wide range of ester, thioester, amide (including an amide derived from an amino acid), hydroxamic acid, hydrazide and sulfoximide, azide and diazoacetyl derivatives. The in vivo activity is presented of a range of these compounds against TLX5 lymphoma and L1210 leukemia cell lines.
Animals↗
Histone deacetylase inhibitors in cancer therapy.
Histone deacetylase inhibitors (HDAC inhibitors) represent a novel class of antineoplastic agents that act by promoting acetylation of histones, leading in turn to uncoiling of chromatin and activation of a variety of genes implicated in the regulation of cell surivival, proliferation, differentiation, and apoptosis. The major classes of HDIs include shortchain fatty acids, hydroxamic acid derivatives, synthetic benzamide derivatives, and cyclic tetrapeptides. Members of each of these classes have now entered clinical trials in humans. Despite their shared capacity to trigger histone deacetylation, individual HDIs exert diverse actions on cell cycle regulatory, signal transduction, and survival-related proteins which in all probability accounts for their disparate actions. Major areas of investigation surrounding HDIs include elucidating the mechanisms by which they induce apoptosis in neoplastic cells, and characterizing the factors responsible for the decision of such cells to undergo maturation versus cell death in the response to these agents. In this context, attention has recently focused on the ability of HDIs to induce perturbations in cell cycle regulatory proteins (e.g., p21(CIP1)), downregulation of survival signaling pathways (e.g., Raf/MEK/ERK), and disruption of cellular redox state (e.g., induction of reactive oxygen species; ROS). Aside from efforts to combine HDIs with established cytotoxic drugs, attempts are underway to establish a rational basis for combining HDIs with differentiation- inducing agents (e.g., ATRA, hypomethylating agents such as 5'-deoxyazacytine) with the goal of triggering re-expression of turn or suppressor and/or differentiation-associated genes. Finally, the results of recent preclinical studies provide a strong rationale for combining HDIs with other novel, molecularly targeted agents, including inhibitors of survival signaling pathways or cell cycle progression. Collectively, these findings should provide a fertile environment for the development of novel HDI-containing regimens in the treatment of cancer for many years to come.
Animals↗
Amino acid derived sulfonamide hydroxamates as inhibitors of procollagen C-proteinase: solid-phase synthesis of ornithine analogues.
A discussion of the solid-phase synthesis of ornithine derived sulfonamide hydroxamic acids is illustrated. These analogues are shown to be potent, non-peptide inhibitors of procollagen C-proteinase (PCP).
Amino Acids↗
Histone deacetylase inhibitors: development as cancer therapy.
Histone deacetylase (HDAC) inhibitors represent a new class of targeted anticancer agents. A number of structural classes of HDAC inhibitors have been developed of which several are in clinical trials, including phenylbutyrate (PB) and related compounds; the hydroxamic acids, suberoylanilide hydroxamic acid (SAHA) and depsipeptide (FK-228); and the benzamides, MS-275 and C1-994. This review will focus on our studies with the hydroxamic acid HDAC inhibitors, of which SAHA is the lead agent. X-ray crystallographic studies with a HDAC homologue (HDLP) demonstrated that the hydroxamic acid group, most of the aliphatic chain and part of the phenyl amino group of SAHA inserts into the pocket-like catalytic site of the enzyme, at the base of which is a zinc molecule. SAHA inhibits the activity of class I and II HDACs and is selective in altering gene expression. SAHA is synergistic in its anticancer activity with radiation, kinase inhibitors, cytotoxic agents and differentiating agents. In phase I clinical trial with orally administered SAHA the agent caused accumulation of acetylated histones in peripheral mononuclear cells and tumour cells, has excellent bioavailability and has shown antitumour activity in patients with haematologic and solid tumours.
Histone Deacetylase Inhibitors↗
Aqueous mixture of pyrrolidone-5-hydroxamic acid-iron (III) complexes: isolation and characterization of tris (pyrrolidone-5-hydroxamato) iron (III).
The published procedure for the synthesis of pyrrolidone-5-hydroxamic acid was improved. The acidity constant of the pyrrolidone-5-hydroxamic acid was determined as pKa = 8.65. In an aqueous solution of iron (III) ions, pyrrolidone-5-hydroxamic acid binds ferric ion, forming a mixture of mono-, bis-, and tris(pyrrolidone-5-hydroxamato)iron (III) complexes. These complexes were studied by potentiometric and spectrophotometric methods. The tris compound was isolated as dark orange-red crystals and identified according to elemental analysis and IR spectral data as C15H21FeN6O9.6H2O, having the magnetic moment of 5.67 B.M.
Chemical Phenomena↗
The Preparation, Characterization, and Magnetism of Copper 15-Metallacrown-5 Lanthanide Complexes.
The preparation and characterization of a series of encapsulated-lanthanide 15-metallacrown-5 complexes are reported. Planar ligands such as picoline hydroxamic acid (picha) or nonplanar alpha-amino hydroxamic acids (e.g., glycine hydroxamic acid (glyha)) led to one-step syntheses of metallacrowns in yields as high as 85%. The reaction of the appropriate hydroxamic acid with copper acetate and (1)/(5) equiv of gadolinium(III) or europium(III) nitrates in DMF or water yielded crystals of Gd(NO(3))(3)[15-MC(Cu(II)N(picha))-5], 1, Eu(NO(3))(3)[15-MC(Cu(II)N(picha))-5], 2, and Eu(NO(3))(3)[15-MC(Cu(II)N(glyha))-5], 3. Several other 15-metallacrown-5 complexes were synthesized with (1) Cu(II) or Ni(II) in the metallacrown ring metal position, (2) various lanthanides (La(III), Nd(III), Sm(III), Eu(III), Gd(III), Dy(III), Ho(III), Er(III), and Yb(III)) encapsulated in the center of the ring, and (3) chiral alpha-amino hydroxamic acids (e.g., phenylalanine hydroxamic acid (H(2)pheha), leucine hydroxamic acid (H(2)leuha), and tyrosine hydroxamic acid (H(2)tyrha)). It is believed that all of the complexes containing Cu(II) ions have the ring metals either in four-coordinate, square-planar environments, bound to two tetradentate hydroximate ligands, or in five-coordinate, square-pyramidal geometries if solvent is bound. Spectroscopic and magnetic characterization of the Ni(II) complexes suggests that they are either five- or six-coordinate. The encapsulated lanthanides are generally pentagonal bipyramidal, with five oxygen donors from the metallacrown ring and solvent or bidentate nitrate ions in the axial positions. The circular arrangement of ions results in interesting magnetic behavior. With Dy(III) encapsulated in the center of the ring, a magnetic moment as high as 10.9 &mgr;(B) is achieved. Analysis of the variable-temperature susceptibility of La(NO(3))(3)[15-MC(Cu(II)N(picha))-5] indicates that the five Cu(II) ions are antiferromagnetically coupled, forming an S = (1)/(2) ground spin state with a moment of 1.7 &mgr;(B) at liquid helium temperatures. Complex 1 shows ferromagnetic coupling of the Gd(III) ion to the five Cu ions at temperatures below 15 K. Studies of the metallacrown complexes in solution show that they are stable and soluble in DMF and water. A proton relaxation study on complex 1 has revealed a relaxivity of 9.8 mM(-)(1) s(-)(1) (20 degrees C and 30 MHz), a value that is comparable to those of clinically useful MRI contrast enhancement agents. Complex 1 crystallizes in the triclinic space group P&onemacr;, with a = 12.657(3) Å, b = 14.833(3) Å, c = 17.707(3) Å, alpha = 79.65(2) degrees, beta = 86.06(2) degrees, gamma = 68.69(2) degrees, V = 3046.6(12) Å, and Z = 2 (R1 = 0.0534, wR2 = 0.1289). Complex 2 crystallizes in the monoclinic space group P2(1)/n, with a = 16.319(2) Å, b = 21.863(2) Å, c = 18.410(3) Å, beta = 96.85(1) degrees, V = 6522(2) Å(3), and Z = 4 (R1 = 0.0463, wR2 = 0.0750). Complex 3 crystallizes in the triclinic space group P&onemacr;, with a = 11. 173(6) Å, b = 11.534(6) Å, c = 13.311(5) Å, alpha = 93.81(3) degrees, beta = 94.82(4) degrees, gamma = 107.20(4) degrees, V = 1625(2) Å(3), and Z = 2 (R1 = 0.1230, wR2 = 0.2979).
Journal Article↗
Synthesis and biological activity of carboxylic acid replacement analogues of the potent angiotensin converting enzyme inhibitor 5(S)-benzamido-4-oxo-6-phenylhexanoyl-L-proline.
The carboxylic acid group on the proline of 1 was replaced by a phosphoric acid, a hydroxamic acid, and a tetrazole to give compounds 2-4, respectively. Testing of 2-4 as angiotensin converting enzyme (ACE) inhibitors gave I50 values of 100, 1.6, and 22 microM, respectively, compared to 0.07 microM for 1. A hydroxamic acid derivative of the ketomethylene pentapeptide analogue 18 was then synthesized. This compound, 17, had an ACE I50 of 0.011 microM compared to 0.0076 microM for 18. Oral administration of 10 mg/kg of 17 to renal hypertensive rats had no effect on blood pressure or heart rate.
Angiotensin-Converting Enzyme Inhibitors↗
Cytodifferentiating agents affect the replication of herpes simplex virus type 1 in the absence of functional VP16.
The herpes simplex virus type 1 (HSV-1) mutant in1814 encodes an altered form of the virion protein VP16 that is unable to transactivate immediate-early (IE) transcription. As a consequence of the mutation, in1814 initiates productive replication inefficiently after infection of tissue culture cells. Previous studies showed that this defect could be overcome by the inclusion in the culture medium of hexamethylene bisacetamide (HMBA), a compound that promotes the differentiation of murine erythroleukemia cells (MELCs). The effects of additional agents known to induce differentiation of MELCs were investigated. N'-Methylnicotinamide, at concentrations optimal for the induction of MELCs, complemented the replication of in1814 and stimulated IE gene expression. Suberoyl bishydroxamic acid and suberoylanilide hydroxamic acid, which induce differentiation of MELCs at micromolar concentrations, did not complement in1814 but specifically blocked the action of HMBA. The histone deacetylase inhibitor trichostatin A, which also induces differentiation of MELCs, antagonized the effect of HMBA in a manner similar to that of suberoyl bishydroxamic acid and suberoylanilide hydroxamic acid. The results demonstrate that the requirement for VP16 activity is dependent on the metabolic state of the host cell and that the pathways leading to complementation of in1814 and differentiation of MELCs are overlapping but not identical.
Acetamides↗
Effect of polymethylene and phenylene linking groups on the DNA cleavage specificity of distamycin-linked hydroxamic acid-vanadyl complexes.
Two types of distamycin-linked hydroxamic acids (DHA), which contain various lengths of polymethylene chains (PM-DHA) and relatively rigid phenylene ones (Ph-DHA), have been synthesized for the first time. Their DNA cleavage specificities were investigated by an end-labeled fragment cleavage experiment in the presence of vanadyl ion and hydrogen peroxide. The DNA cleavage by the PM-DHA x VO(II) complexes was shown to be very dependent on the length of the chain and the AT sequences. The tetramethylene DHA (1b) complex exhibited highly specific cleavage patterns flanking the 8 and 10 AT sites. Interestingly, the Ph-DHA complexes selectively cleaved the 5' end-labeled strand at the AT sites, but did not cleave the 3' end-labeled strand. The vanadyl complexing moieties and the local sequence conformation of the AT tract are suggested to contribute significantly to the DNA recognition of the PM-DHA x VO(II) complexes.
Animals↗
Hydroxamic acid-containing hydrogels for nonabsorbed iron chelation therapy: synthesis, characterization, and biological evaluation.
Iron overload is a severe clinical condition and can be largely prevented by the use of iron-specific chelating agents. A successful iron chelator needs to be orally active, nontoxic, and selective. In this study, hydrogels containing pendant hydroxamic acid groups have been synthesized as potential nonabsorbed chelators for iron in the gastrointestinal tract. The synthetic method employed to introduce hydroxamic acid groups to polymer chains involved reaction of polymer gels based on N-acryloxysuccinimide, acryloyl chloride, and (2-hydroxyethyl)acrylate monomers with hydroxylamine. These hydroxamic acid-functionalized polymer gels swell favorably in water and effectively sequester iron. In vitro iron-binding properties of these hydrogels were evaluated from their binding isotherms by use of iron(II) alone and in the presence of other competing metal ions. These polymers bind iron over a broad pH range. The iron-binding properties of the polymers were found to depend on the concentration of hydroxamate groups on polymer chains. The in vivo iron-binding efficacy of the polymers was evaluated in rat as the animal model. The polymers prevented an increase in serum hemoglobin and hematocrit levels in the animals, thus suggesting the prevention of systemic absorption of dietary iron from the gastrointestinal tract. The animals also maintained normal body weight during the treatment period, indicating the absence of any apparent toxicity associated with these polymers.
Acrylamides↗
[Benzo[c][2,7]naphthyridines from 2,6-dinor-nifedipine and its dimethyl 2,5-dicarboxylate isomer].
The reaction of 2-nitrobenzaldehyde with methyl propiolate and ammonium acetate in acetic acid yields 2,6-dinor-nifedipine (1a) and the isomeric rac. 1,4-dihydropyridine (DHP) 1b. The DHP 1 are dehydrogenated both chemically and by anodic oxidation using a rotating platinum electrode (RPE) by means of differential pulse voltammetry (DPV) affording the corresponding pyridines 2a, b. Compound 1a is more stable, while compound 1b is less stable than nifedipine. Irradiation of the DHP 1 with UV-A light forms the nitrosophenyl-pyridines 3, which cyclize after addition of conc. hydrochloric acid to yield the chloro substituted hydroxamic acids 4a, b. The hydroxamic acids 4c, d are obtained treating 2a, b with zinc in acetate buffer pH 4.6. The hydroxamic acids 4b, d demonstrate only a moderate inhibition of 5-lipoxygenase (5-LOX) of human whole blood compared with the activity of the reference compound zileutone. The formation of 15-HETE is also inhibited. Compound 4a reduces the activity of cyclooxygenase. The lactames 5, obtained from the hydroxamic acids 4 by desoxygenation with phosphorus trichloride, react with phosphoryl chloride to give compounds 6, representing educts for potential agents against malaria.
Antimalarials↗
Cytochrome c/H2O2-mediated one electron oxidation of carcinogenic N-fluorenylacetohydroxamic acids to nitroxyl free radicals.
The oxidation of carcinogenic hydroxamic acids, N-hydroxy-N-2-fluorenylacetamide (N-OH-2-FAA) and N-hydroxy-N-3-fluorenylacetamide (N-OH-3-FAA) catalyzed by horseradish peroxidase (HRP) or cytochrome c in the presence of H2O2 was investigated. HRP/H2O2 was a more efficient system in oxidation of both hydroxamic acids and the standard substrate, guaiacol, then cytochrome c/H2O2. Peroxidative activity of cytochrome c was shown after incubation with Triton X-100 and H2O2 for 20 min at room temperature in 0.05 M phosphate buffer (pH 7.5) or in 0.1 M sodium acetate (pH 6.0) without Triton X-100. Both hydroxamic acids were oxidized to nitroxyl free radicals as shown by electron spin resonance (ESR) spectroscopy. These radicals dismutated to equimolar amounts of 2- or 3-nitrosofluorene and acetate esters of the corresponding hydroxamic acids as shown by thin layer chromatography and spectrophotometric analysis of the products. In addition, large amounts of the N-fluorenylamides were generated in the reactions with cytochrome c/H2O2 system. Of the products, only 2- or 3-nitrosofluorene per se or when generated from the oxidation of the hydroxamic acids, interacted with lecithin (1 mg/ml) to yield ESR signals of the immobilized nitroxyl free radicals. In contrast to HRP/H2O2 system, in which the initial velocity of the radical formation was too fast to measure and the maximal concentrations of the nitroxyl free radicals of both hydroxamic acids were similar, in the cytochrome c/H2O2 system the nitroxyl free radical of N-OH-2-FAA formed at a 6-fold faster rate and accumulated at a 2-fold higher concentration than the radical of N-OH-3-FAA. In both enzyme systems, the persistence of the signal and the length of time before it had decreased to one half its maximum were several-fold longer for the nitroxyl free radical of N-OH-3-FAA than for that of N-OH-2-FAA. These data showed that these nitroxyl free radicals differed in their kinetic properties. One electron oxidation of N-OH-3-FAA by HRP/H2O2 system and of both isomeric hydroxamic acids by cytochrome c/H2O2 system are reported for the first time in this work and may be considered an activation reaction in carcinogenesis by these compounds.
Cytochrome c Group↗
Sequence specificity of DNA cleavage by bisnetropsin-linked hydroxamic acid-metal complexes: highly specific cleavage by ferrous complexes.
Bisnetropsin-linked hydroxamic acids (BNHA) were shown to cleave DNA stands at a single residue with a preferred binding orientation in the presence of ferrous ion. In contrast, the corresponding cerium (III) complexes cleaved DNA with low sequence specificity.
Base Sequence↗